WAVEMAN · COMPANY

MDXG · Mimedx Group, Inc.

LIVE

TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475

← ALL COMPANIES

MDXG

Name: MIMEDX GROUP, INC. (MDXG) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

MIMEDX GROUP, INC.

MEDICAL DEVICES · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · CIK 0001376339

SEC FILINGS☆ WATCH

INSIDER NET · 180D

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

128

13F, latest reported quarter

REVENUE GROWTH

+20.0%

XBRL, annual

NET MARGIN

11.6%

CONVERSIONS · 180D

codes C/M, not in net · $1.9M priced

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

no Form 4 purchases or sales on file

CONGRESS

no member of Congress has reported trading it

FUNDS

128 funds added or opened last quarter

more than 63% of Medical Devices

REVENUE

+20.0% year over year

more than 76% of Medical Devices

MARGIN

11.6% net margin

more than 80% of Medical Devices

BUYBACKS

$12.5M repurchased, FY to 2026-06-30

below 62% of Medical Devices

SHORT

5.8% of shares outstanding short · 5.3 days to cover · settled 2026-07-31

more than 69% of Medical Devices

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

128 funds added or opened positions in the latest 13F quarter, of 228 holders.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN -36.4%

-36.4%12M

INSIDER SELL

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

The complete filing record, in one place.

The record shows 128 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

TMO PEN ROK BLFS MTD SIBN WRBY ISRG TXG DXCM EW TMDX

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for MIMEDX GROUP, INC. in the period covered. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER

FILED

VALUE

Maersk-Moller Kimberly

Chief Commercial Officer

SELL

2025-11-06

58,300.0

$432.6K

Capper Joseph H

Chief Executive Officer

BUY

2025-05-02

200,000.0

$1.3M

Maersk-Moller Kimberly

Chief Commercial Officer

SELL

2025-03-17

1,759.0

$14.1K

Hulse William Frank IV

General Counsel and CAO

SELL

2025-03-13

34,230.0

$270.1K

Hulse William Frank IV

General Counsel and CAO

SELL

2025-03-13

20,366.0

$160.7K

64 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 59 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

Essex Woodlands Management, Inc.

28,195,249.0 sh

$108.6M

BlackRock, Inc.

12,154,466.0 sh

$46.8M

Nantahala Capital Management, LLC

9,535,104.0 sh

$36.7M

Trigran Investments, Inc.

7,173,770.0 sh

$27.6M

STATE STREET CORP

5,578,920.0 sh

$21.5M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Paradigm Micro-Cap Fund

$1.2M POSITION · AS OF 2026-03-31

0.9%

AUER GROWTH

$489.0K POSITION · AS OF 2026-02-28

0.7%

Victory Integrity Discovery Fund

$265.8K POSITION · AS OF 2026-03-31

0.4%

Invesco NASDAQ Future Gen 200 ETF

$46.9K POSITION · AS OF 2026-02-28

0.3%

ACUITAS US MICROCAP FUND

$319.6K POSITION · AS OF 2026-03-31

0.3%

Schwab Small-Cap Equity Fund

$1.9M POSITION · AS OF 2026-04-30

0.3%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Clinical pipeline

ClinicalTrials.gov · 4 registered trials, 2 still enrolling or running — a status change here is dated weeks before the press release

Phase 2

0 ACTIVE

Not applicable

2 ACTIVE

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Corporate PAC

FEC · the company-connected political action committee's own receipts and spending — committee totals only, never individual donors

Mimedx Group, Inc. Pac

CYCLE 2026 · $0K SPENT

FEDERAL ELECTION COMMISSION · MATCHED BY THE PAC'S CONNECTED ORGANISATION

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$418.6M	$348.9M	$321.5M	$267.8M
GROSS PROFIT	$345.6M	$288.8M	$266.8M	$219.5M
OPERATING INCOME	$63.9M	$58.9M	$37.1M	$-14.7M
NET INCOME	$48.6M	$42.4M	$58.2M	$-30.2M
EPS (DILUTED)	0.32	0.28	0.37	-0.33
OPERATING CASH FLOW	$74.0M	$66.2M	$26.8M	$-17.9M
CASH	$166.1M	$104.4M	$82.0M	$66.0M
LONG-TERM DEBT	$16.5M	$17.8M	$48.1M	$48.6M
BUYBACKS	$0	$0	$9.5M	$0

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE